BioCardia and Helix are seeking regulatory approval from the FDA and CE-mark in Europe for their respective medical products.
1 report, 1 independent
Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioCardia and Helix are seeking regulatory approval from the FDA and CE-mark in Europe for their respective medical products.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BioCardia (United States)
company in San Carlos, United States
Nothing else this week.
-
Helix
Population genomics startup based in San Carlos, California
Nothing else this week.
- FDA
Related events
- Breakthrough is expanding its clinical trials across Europe and receiving FDA approval for its devices.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- FDA and Pfizer are seeking regulatory approval for their products.
Coverage
Newest first; wire copies grouped- GlobeNewswireBioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter SU